"Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumours.This allows specific delivery of cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells."
The PAB qtrly report has some interest to us with our research collaboration between companies. It is sounding upbeat with the "Can be used" language There may be more detail in our qrtly report.
IBX Price at posting:
1.2¢ Sentiment: Buy Disclosure: Held
